Lives unaffected by cystic fibrosis

Clinical Trial Finder

Be a part of the movement transforming the future of cystic fibrosis treatment.

Clinical trials are listed below.

  • Restore CFTR FunctionCompleted with results Location: Multiple US sites

    Phase 2 study of VX-152 combination drug in people with cystic fibrosis. , protocol number Vertex VX-152-102

    This study is taking place at multiple care centres accross the US. It will look at the safety and tolerability of the drug VX-152 in combination with both ivacaftor and tezacaftor (VX-661).

    • Age:

      18 years and older

    • Mutation(s):

      homozygous or hetrozygous F508del

    • FEV1% Predicted:

      40 - 90%

    • Number of Visits:

      10

    • Length of Participation:

      16 weeks

    Contact us about this clinical Trial >
  • Restore CFTR FunctionEnrolling Location: Multiple care centres across the US

    Phase 1/2 Study of PTI-801 drug in healthy adults and then in adults with cystic fibrosis. , protocol number Proteostasis Therapeutics NCT03140527 PTI-801-01

    This study is taking place at multiple care centres across the US. It will look at the safety and tolerability of the drug PTI-801

    • Age:

      18 years and over

    • Mutation(s):

      No mutation requirement

    • FEV1% Predicted:

      40 - 90%

    • Number of Visits:

      8

    • Length of Participation:

      30

    Contact us about this clinical Trial >
  • Restore CFTR FunctionEnrolling Location: Multiple US sites

    Phase 3 study of tezacaftor (VX-661) combination drug in children with cystic fibrosis. , protocol number Vertex VX15-661-113

    This two-part study is taking place at multiple care centres across the US. It will look at the safety and tolerability of the drug tezacaftor (VX-661) in combination with ivacaftor. It will also look at how the body processes the drug.

    • Age:

      6-11 years

    • Mutation(s):

      homozygous or hetrozygous F508del

    • FEV1% Predicted:

      40% or greater

    • Number of Visits:

      9

    • Length of Participation:

      28 weeks

    Contact us about this clinical Trial >
  • ObservationalEnrolling Location: Australia, Melbourne

    Multi Breath Nitrogen Washout (MBNW) as a Measure of Small Airway Function in Patients With Respiratory Disease , protocol number NCT00163696

    Measurements of Inhomogeneity of the Small Airway With Patients With Cystic Fibrosis, Asthma and Bronchiolitis Obliterans Syndrome (Post Transplant) Using the Multi Breath Nitrogen Washout Technique

    • Age:

      18-65 years

    • Mutation(s):

      Not specified

    • FEV1% Predicted:

      Not Specified

    • Number of Visits:

      Not specified

    • Length of Participation:

      Not Specified

    Contact us about this clinical Trial >
  • OtherActive, not recruiting Location: USA

    Viral pathogenisis of early cystic fibrosis lung disease , protocol number NCT01973192 1R01HL116211-01

    Study will test the hypothesis that early viral infections alter the bacterial flora and inflammatory profile in the airway and accelerate progression of pulmonary disease in infants with cystic fibrosis.

    • Age:

      2-4 months

    • Mutation(s):

      Hetrozygous

    • FEV1% Predicted:

      Not Specified

    • Number of Visits:

      Not specified

    • Length of Participation:

      Not Specified

    Contact us about this clinical Trial >
  • Anti-InfectiveEnrolling Location: USA

    STOP 2: Treatment of pulmonary exacerbations in people with CF , protocol number STOP2-1P-15

    This study is taking place at multiple care centers across the U.S. It will look at the safety and effectivness of different lengths of IV treatment for pulmonary exacerbations in people with CF.

    • Age:

      18 Years and Older

    • Mutation(s):

      No Mutation Requirement

    • FEV1% Predicted:

      25 to 100%

    • Number of Visits:

      3

    • Length of Participation:

      35 days

    Contact us about this clinical Trial >
  • Restore CFTR FunctionEnrolling Location: Multiple care centres across the US (healthy volunteers) & Belfast (CF)

    Phase I Study of PTI-808 and triple combination in healthy adults and then in adults with cystic fibrosis , protocol number NCT03500263 PTI-808-01 Proteostasis

    Parts 1 and 2 of this study will take place in healthy volunteers. Part 3 of this study is taking place in adults with cystic fibrosis at multiple care centers across the U.S. It will look at the safety, tolerability, and how the body processes the drug in multiple ascending doses of PTI-808 and PTI-808 together with PTI-428 and PTI-801.

    • Age:

      18 years and older

    • Mutation(s):

      Two copies of F508del

    • FEV1% Predicted:

      40-90%

    • Number of Visits:

      10

    • Length of Participation:

      56 days

    Contact us about this clinical Trial >
  • Restore CFTR FunctionClosed to enrollment Location: USA

    Phase 1 exploratory study on the effect of the drug QR-010 on nasal cells. , protocol number NCT02564354 PQ-010-002

    This study is taking place at multiple care centers across the U.S. It will explore whether the drug QR-010 administered through nasal spray can increase the movement of salt in and out of the nasal cells.

    • Age:

      18 Years and Older

    • Mutation(s):

      Two copies F508del or One Copy F508del

    • FEV1% Predicted:

      40% or greater

    • Number of Visits:

      8

    • Length of Participation:

      7 weeks

    Contact us about this clinical Trial >
  • Restore CFTR FunctionEnrolling Location: USA

    SN06: Phase 2 study of N91115 in adults with CF who are currently taking lumacaftor/ivacaftor. , protocol number Nivalis N91115-2CF1-05

    This study is taking place at multiple care centers across the U.S. It will test the safety and effectiveness of a new type of CFTR modulator drug called N91115 in adults with cystic fibrosis who are currently taking lumacaftor/ivacaftor. It will also look at how the body processes the drug.

    • Age:

      18 Years and Older

    • Mutation(s):

      Two copies F508del

    • FEV1% Predicted:

      40 to 85%

    • Number of Visits:

      10

    • Length of Participation:

      16 weeks

    Contact us about this clinical Trial >
  • Restore CFTR FunctionEnrolling Location: USA

    SN07: Phase 2 study of N91115 in adults with CF who are currently taking ivacaftor , protocol number Nivalis N91115-2CF-06

    This study is taking place at multiple care centers across the U.S. It will look at the safety and effectiveness of the oral drug N91115 and will use a placebo control.

    • Age:

      18 Years and Older

    • Mutation(s):

      One Copy F508del or No Copies F508del

    • FEV1% Predicted:

      40 to 90%

    • Number of Visits:

      8

    • Length of Participation:

      12 weeks

    Contact us about this clinical Trial >
  • Displaying results 91-100 (of 165)
     |<  <  6 - 7 - 8 - 9 - 10 - 11 - 12 - 13 - 14 - 15  >  >|